Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 312.7 Thousand USD | -48.36% |
| 2022 | 624.52 Thousand USD | -21.66% |
| 2021 | 797.2 Thousand USD | -11.31% |
| 2020 | 898.91 Thousand USD | -8.24% |
| 2019 | 979.65 Thousand USD | 688.69% |
| 2018 | 124.21 Thousand USD | 54.34% |
| 2017 | 80.47 Thousand USD | 21.24% |
| 2016 | 66.37 Thousand USD | 4.77% |
| 2015 | 63.35 Thousand USD | -2.29% |
| 2014 | 64.84 Thousand USD | 1.23% |
| 2013 | 64.05 Thousand USD | 33.5% |
| 2012 | 47.97 Thousand USD | -99.36% |
| 2011 | 7.55 Million USD | 7536.64% |
| 2010 | 98.9 Thousand USD | 182.49% |
| 2009 | 35.01 Thousand USD | 26.46% |
| 2008 | 27.68 Thousand USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 126.84 Thousand USD | -60.67% |
| 2024 Q2 | - USD | -100.0% |
| 2023 Q4 | 322.51 Thousand USD | -37.71% |
| 2023 FY | 322.51 Thousand USD | -48.36% |
| 2023 Q1 | 414.54 Thousand USD | -33.62% |
| 2023 Q2 | 255.99 Thousand USD | -38.25% |
| 2023 Q3 | 517.75 Thousand USD | 102.25% |
| 2022 Q1 | 568.63 Thousand USD | -28.67% |
| 2022 Q3 | 831.49 Thousand USD | 108.82% |
| 2022 FY | 624.52 Thousand USD | -21.66% |
| 2022 Q4 | 624.52 Thousand USD | -24.89% |
| 2022 Q2 | 398.17 Thousand USD | -29.98% |
| 2021 Q4 | 797.2 Thousand USD | -21.97% |
| 2021 FY | 797.2 Thousand USD | -11.31% |
| 2021 Q3 | 1.02 Million USD | 74.98% |
| 2021 Q2 | 583.86 Thousand USD | -21.38% |
| 2021 Q1 | 742.6 Thousand USD | -17.39% |
| 2020 Q4 | 898.91 Thousand USD | -24.15% |
| 2020 FY | 898.91 Thousand USD | -8.24% |
| 2020 Q3 | 1.18 Million USD | 33.66% |
| 2020 Q2 | 886.63 Thousand USD | 2.33% |
| 2020 Q1 | 866.43 Thousand USD | -11.56% |
| 2019 FY | 979.65 Thousand USD | 688.69% |
| 2019 Q1 | 209.99 Thousand USD | 69.06% |
| 2019 Q2 | 769.01 Thousand USD | 266.21% |
| 2019 Q3 | 938.7 Thousand USD | 22.07% |
| 2019 Q4 | 979.65 Thousand USD | 4.36% |
| 2018 Q4 | 124.21 Thousand USD | -34.76% |
| 2018 Q2 | 20.91 Thousand USD | -69.14% |
| 2018 Q1 | 67.76 Thousand USD | -15.8% |
| 2018 FY | 124.21 Thousand USD | 54.34% |
| 2018 Q3 | 190.4 Thousand USD | 810.52% |
| 2017 Q2 | 2.42 Million USD | 3754.63% |
| 2017 FY | 80.47 Thousand USD | 21.24% |
| 2017 Q4 | 80.47 Thousand USD | -96.82% |
| 2017 Q3 | 2.52 Million USD | 4.36% |
| 2017 Q1 | 62.84 Thousand USD | -5.32% |
| 2016 Q4 | 66.37 Thousand USD | -40.58% |
| 2016 FY | 66.37 Thousand USD | 4.77% |
| 2016 Q1 | 78.8 Thousand USD | 24.38% |
| 2016 Q2 | 34.77 Thousand USD | -55.87% |
| 2016 Q3 | 111.7 Thousand USD | 221.2% |
| 2015 Q2 | 34.76 Thousand USD | -56.21% |
| 2015 FY | 63.35 Thousand USD | -2.29% |
| 2015 Q4 | 63.35 Thousand USD | -98.76% |
| 2015 Q3 | 5.1 Million USD | 14596.44% |
| 2015 Q1 | 79.39 Thousand USD | 22.44% |
| 2014 Q1 | 80.32 Thousand USD | 25.41% |
| 2014 Q2 | 35.77 Thousand USD | -55.46% |
| 2014 FY | 64.84 Thousand USD | 1.23% |
| 2014 Q4 | 64.84 Thousand USD | -40.82% |
| 2014 Q3 | 109.56 Thousand USD | 206.26% |
| 2013 FY | 64.05 Thousand USD | 33.5% |
| 2013 Q4 | 64.05 Thousand USD | -40.81% |
| 2013 Q3 | 108.22 Thousand USD | -23.95% |
| 2013 Q1 | 67.28 Thousand USD | 40.24% |
| 2013 Q2 | 142.3 Thousand USD | 111.51% |
| 2012 Q4 | 47.97 Thousand USD | -45.78% |
| 2012 Q2 | 2.09 Million USD | 147.35% |
| 2012 Q1 | 845.48 Thousand USD | -88.81% |
| 2012 FY | 47.97 Thousand USD | -99.36% |
| 2012 Q3 | 88.49 Thousand USD | -95.77% |
| 2011 Q2 | 4.56 Million USD | 46.85% |
| 2011 FY | 7.55 Million USD | 7536.64% |
| 2011 Q1 | 3.1 Million USD | 3043.36% |
| 2011 Q3 | 6.1 Million USD | 33.7% |
| 2011 Q4 | 7.55 Million USD | 23.73% |
| 2010 Q1 | 59.57 Thousand USD | 70.16% |
| 2010 FY | 98.9 Thousand USD | 182.49% |
| 2010 Q4 | 98.9 Thousand USD | -37.7% |
| 2010 Q3 | 158.76 Thousand USD | -84.59% |
| 2010 Q2 | 1.03 Million USD | 1629.47% |
| 2009 Q4 | 35.01 Thousand USD | -51.34% |
| 2009 FY | 35.01 Thousand USD | 26.46% |
| 2009 Q1 | 54.7 Thousand USD | 97.57% |
| 2009 Q2 | 131.85 Thousand USD | 141.05% |
| 2009 Q3 | 71.94 Thousand USD | -45.44% |
| 2008 Q2 | 69.21 Thousand USD | 0.0% |
| 2008 FY | 27.68 Thousand USD | 0.0% |
| 2008 Q4 | 27.68 Thousand USD | -47.72% |
| 2008 Q3 | 52.96 Thousand USD | -23.48% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q3 | 521.31 Thousand USD | -8.26% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q2 | 568.26 Thousand USD | 2.14% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | 556.36 Thousand USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q4 | - USD | -100.0% |
| 2003 Q2 | 85.45 Thousand USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | 85.45 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | 36.828% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -14.125% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 99.74% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 85.201% |
| Azitra, Inc. | 885.94 Thousand USD | 64.704% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -681.777% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | 75.352% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 95.679% |
| CEL-SCI Corporation | 13.57 Million USD | 97.696% |
| iBio, Inc. | 4.46 Million USD | 92.989% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 89.407% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 91.206% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 87.154% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 88.587% |
| NanoViricides, Inc. | - USD | -Infinity% |
| BiomX Inc. | 15.09 Million USD | 97.928% |
| BiomX Inc. | 15.09 Million USD | 97.928% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 98.81% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | 47.03% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 97.773% |